Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.KineMed has agreed to collaborate with Merck Serono, a division of Merck KGaA, to discover new applications for drug candidates.
Subscribe to our email newsletter
In the collaboration, Californian drug developer KineMed will identify new therapeutic utility in in vivo preclinical models by applying its proprietary translational medicine technologies. Once a disease target is established for a selected drug candidate, KineMed and Merck KGaA will jointly determine the best development and commercialization path for the development candidates being studied.
Under the terms of the agreement, KineMed will receive from Merck an upfront payment, milestones and royalty payments on products advanced with KineMed's technology. Additional terms of the deal were not disclosed.